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INTRODUCTION
The human genome comprises approximately 23,000 protein1
coding genes. For over thirty years, the United States Patent and
Trademark Office (PTO) has issued patents on isolated
* Senior Staff Member, American University Law Review, Volume 61; J.D.
Candidate, May 2012, American University, Washington College of Law; Ph.D., Cancer
Biology, 2009, Vanderbilt University; B.A., Biology, 2003, University of Virginia; USPTO
Registration Number 65,168. Many thanks to the staff of the American University Law
Review for their efforts in bringing this piece to publication. I would especially like to
thank Dr. Richard Peek, Jr. and his laboratory for all they taught me during my
pursuit of a Ph.D. and my parents for their continuing support of a “perpetual”
student.
1. Int’l Human Genome Sequencing Consortium, Finishing the Euchromatic
Sequence of the Human Genome, 431 NATURE 931, 942 (2004).
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deoxyribonucleic acid (DNA) molecules encoding sequences
2
As a result,
identical to human genes as found in nature.
approximately 20% of all human genes are patented, some as many
3
as twenty times. A number of patents claim isolated DNA molecules
encoding mutations that increase a person’s risk of developing
4
disease, making them useful tools for genetic testing. Proponents of
gene patenting assert that such patents stimulate investment and
research by rewarding scientists with exclusive rights in their
5
invention. Opponents, on the other hand, argue that gene patents
impede access to patient testing, decrease the quality of genetic
6
testing, and create barriers to research.
7
Though the statutory definition of patentable material has been
2. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office (Myriad),
653 F.3d 1329, 1355, 99 U.S.P.Q.2d (BNA) 1398, 1418 (Fed. Cir. 2011).
3. Kyle Jensen & Fiona Murray, Intellectual Property Landscape of the Human
Genome, 310 SCI. 239, 239 (2005). The subject matter of gene patenting is not the
genes themselves, but isolated DNA molecules comprising sequences identical to the
sequences of the human gene as found in nature, a composition of matter. See, e.g.,
Myriad, 653 F.3d at 1351, 99 U.S.P.Q.2d (BNA) at 1415 (providing an example of a
claimed isolated DNA molecule and describing the relationship between isolated
DNA sequences and naturally occurring DNA or genes). As used in this Note, “gene
patents” or “gene patenting” refer to the patenting of the isolated DNA molecule,
not to the gene sequence itself.
4. See Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 702 F.
Supp. 2d 181, 195, 94 U.S.P.Q.2d (BNA) 1683, 1693 (S.D.N.Y. 2010) (discussing the
connection between genetic mutations and the propensity for particular diseases),
aff’d in part, rev’d in part, 653 F.3d 1329, 99 U.S.P.Q.2d (BNA) 1398 (Fed. Cir. 2011).
5. See Myriad Defendants’ Memorandum of Law (1) in Support of Their Motion
for Summary Judgment & (2) in Opposition to Plaintiffs’ Motion for Summary
Judgment at 46, Ass’n for Molecular Pathology, 702 F. Supp. 2d 181, 94 U.S.P.Q.2d
(BNA) 1683 (No. 09 Civ. 4515), 2009 WL 5785008 at *53 [hereinafter Myriad’s
Memo] (indicating that at least 8600 research papers have been directed toward
Myriad’s claimed gene sequences since their disclosure); SEC’Y’S ADVISORY COMM. ON
GENETICS, HEALTH, & SOC’Y, U.S. DEP’T OF HEALTH & HUMAN SERVS., GENE PATENTS
AND LICENSING PRACTICES AND THEIR IMPACT ON PATIENT ACCESS TO GENETIC TESTS 28–
29 (2010) [hereinafter SACGHS REPORT], available at http://oba.od.nih.gov/oba/
SACGHS/reports/SACGHS_patents_report_2010.pdf (summarizing legal and
economic scholarship and public comments supporting the view that patents
stimulate investment in genetic testing); Lisa A. Haile, IP Position Critical to Biotech
Investment, WALL STREET BIOBEAT (Apr. 1, 2010), http://www.genengnews.com/genarticles/ip-position-critical-to-biotech-investment/3235/ (noting that the strength of
a company’s intellectual property strategy and position is one of the top three
questions posed by investors).
6. See, e.g., SACGHS REPORT, supra note 5, at 39–45 (explaining that limited
access arises in the context of a sole testing provider because lack of competition
inflates prices above what insurance companies will cover); Steve Benowitz, French
Challenge to BRCA1 Patent Underlies European Discontent, 94 J. NAT’L CANCER INST. 80–81
(2002) (finding that Myriad’s testing procedure failed to detect ten to twenty percent
of mutations); John P. Walsh et al., View from the Bench: Patents and Materials Transfers,
309 SCI. 2002, 2002 (2005) (determining that out of 381 academic scientists, none
stopped their research due to the existence of patents).
7. 35 U.S.C. § 101 (2006) (providing that a patent is available for new and
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broadly construed, the United States Supreme Court has recognized
three judicially-created exceptions to patentability: laws of nature,
8
physical phenomena, and abstract ideas. Recently, the United States
District Court for the Southern District of New York determined that
claims to isolated DNA molecules cover patent-ineligible products of
nature, asserting that as the physical embodiment of biological
information, DNA represents the physical embodiment of laws of
9
nature. In Ass’n for Molecular Pathology v. United States Patent &
10
Trademark Office (Myriad), the United States Court of Appeals for the
Federal Circuit reversed the district court’s decision, holding that
11
claims to such isolated DNA are patentable subject matter. Through
scientific analysis, the court reasoned that the chemical and structural
differences between isolated DNA molecules and DNA as found in
nature were “distinctive,” rendering isolated DNA molecules patent12
eligible.
This Note examines the Myriad decision, analyzing the science
behind isolated DNA in light of historical Supreme Court
jurisprudence regarding the patentability of inventions derived from
nature. Part I examines the science of DNA and sets forth the facts
and procedural history of the case. Part II argues that Supreme
Court decisions regarding the patentability of inventions derived
from nature require an assessment of the differences between the
claimed subject matter and that found in nature. Part II further
argues that the Federal Circuit correctly found that isolated DNA
molecules are patent-eligible under this analysis, and that the Myriad
decision supports stability within the patent system. This Note
concludes that by following the analytical framework set forth in
Myriad, which emphasizes the differences between an invention and a
useful inventory and discoveries, or new and useful improvements on existing
patents).
8. See Diamond v. Chakrabarty, 447 U.S. 303, 309, 206 U.S.P.Q. (BNA) 193, 197
(1980) (citing Parker v. Flook, 437 U.S. 584, 198 U.S.P.Q. (BNA) 193 (1978);
Gottschalk v. Benson, 409 U.S. 63, 67, 175 U.S.P.Q. (BNA) 673, 675 (1972); Funk
Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S. 127, 130, 76 U.S.P.Q. (BNA) 280, 281
(1948); O’Reilly v. Morse, 56 U.S. (15 How.) 62, 112–21 (1854); Le Roy v. Tatham,
55 U.S. (14 How.) 156, 175 (1853)) (providing examples of such exceptions of a new
mineral found in the earth, a new plant found in the wild, Einstein’s law that E=mc2,
and Newton’s law of gravity).
9. See Ass’n for Molecular Pathology, 702 F. Supp. 2d at 228, 94 U.S.P.Q.2d (BNA)
at 1719 (holding invalid claims to not only isolated DNA molecules comprising
sequences identical to those found in nature but also cDNA, which is synthesized
from a natural template).
10. 653 F.3d 1329, 99 U.S.P.Q.2d (BNA) 1398 (Fed. Cir. 2011).
11. Id. at 1352–54, 99 U.S.P.Q.2d (BNA) at 1416–17.
12. Id. at 1350–51, 99 U.S.P.Q.2d (BNA) at 1415.
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product of nature, courts will promote scientific progress by avoiding
fundamental changes to more than a century of precedent and PTO
practice in the field of biotechnology.
I.

BACKGROUND

A. The Science of DNA
DNA exists in nature as linear sequences of nucleotides (chemical
units that include one of four bases: adenine, thymine, guanine, and
13
cytosine) that are packaged into chromosomes. Each chromosome
contains hundreds of genes, occurring one after the other as discrete
14
lengths of sequence within the linear DNA.
The order of the
nucleotide sequences within a gene determines the function of the
protein produced by that gene, and the characteristics of individual
15
proteins collectively contribute to the genetic traits of a person.
During transcription, DNA is copied repeatedly into a similar form
16
known as messenger RNA (mRNA).
Subsequently, during
translation, protein is synthesized according to the mRNA
17
templates. The resulting proteins then interact to perform a host of
functions within the cell. A simple analogy illustrates the concept: a
person reads instructions (DNA) for how to put a table together, and
that person’s brain processes the information (transcription) into a
signal (mRNA); that signal (mRNA) instructs the body to carry out
the processed instructions from the brain to put the table’s
components (proteins) together (translation).
Importantly, alterations of the nucleotide sequences, called
18
mutations, can occur. Genetic mutations can increase a person’s
19
risk of developing a variety of serious diseases, including cancer.
13. HARVEY LODISH ET AL., MOLECULAR CELL BIOLOGY 8, 101–03 (4th ed. 2001).
14. Id. at 4, 8.
15. See id. at 5, 100–01 (discussing the central dogma of molecular biology—the
sequence of DNA directs the synthesis of RNA, which then directs assembly of
proteins).
16. See id. at 111–16 (providing an overview of transcription).
17. See id. at 116–19, 127 (providing an overview of translation). DNA includes
both coding (“exons”) and non-coding (“introns”) lengths of nucleotide sequence.
Id. at 116. During transcription, introns are excised (“spliced”) from mRNA, leaving
only the exons. Id. cDNA, synthesized from an mRNA template in the laboratory,
contains only the sequence of the exons, an important distinction noted in all three
opinions produced by the Myriad court. Id. at 219.
18. Id. at 254.
19. Id. at 258–59, 1061; see also Marisa Noelle Pins, Note, Impeding Access to Quality
Patient Care and Patient Rights: How Myriad Genetics’ Gene Patents Are Unknowingly
Killing Cancer Patients and How to Calm the Ripple Effect, 17 J. INTELL. PROP. L. 377, 384
(2010) (noting that, though some inherited mutations are innocuous, others may
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20

the gene at issue in
Likewise, specific mutations of BRCA1/2,
21
Myriad, increase the risk of breast and ovarian cancer. Because an
increased risk for breast or ovarian cancer has implications for an
individual’s choice of lifestyle and preventative care, the scientific
and healthcare communities are intensifying research into genetic
testing to facilitate early identification of BRCA1/2 mutations in
22
patients.
Current testing relies on the isolated DNA molecules
23
encoding BRCA1/2 gene sequences claimed by Myriad’s patents.
B. Facts and Procedural History
24

Myriad Genetics (“Myriad”) holds several patents, claiming, inter
25
alia, isolated DNA molecules encoding the human BRCA1/2 genes.
A representative composition claim reads, “[a]n isolated DNA coding
for a BRCA1 polypeptide, said polypeptide having the [following]
26
amino acid sequence.” Certain mutations of the BRCA1/2 genes
increase a person’s risk for a variety of diseases).
20. BRCA1 and BRCA2 stand for “breast cancer 1, early onset,” and “breast
cancer 2, early onset,” respectively. See, e.g., Homo Sapiens Breast Cancer 2, Early Onset
(BRCA2), mRNA, NIH NCBI GenBank, http://www.ncbi.nlm.nih.gov/nuccore/
NM_000059.3 (last visited Nov. 14, 2011).
21. The average woman in the United States, without such a mutation, has about
a 12% chance of developing breast cancer in her lifetime, but carriage of an
abnormal BRCA1 or BRCA2 gene augments this to about an 80% chance. Genetics,
BREASTCANCER.ORG, http://www.breastcancer.org/risk/factors/genetics.jsp (last
modified Feb. 15, 2011). Such mutations also increase a woman’s risk for developing
ovarian, colon, pancreatic, and thyroid cancers. Id.
22. See, e.g., Study Groups, CIMBA (THE CONSORTIUM OF INVESTIGATORS OF
MODIFIERS OF BRCA1/2), http://www.srl.cam.ac.uk/consortia/cimba/groups/
groups.html (last visited Nov. 2, 2011) (listing fifty-one members worldwide of a
scientific consortium for researching BRCA1/2).
23. See SACGHS REPORT, supra note 5, at 23 (noting that Myriad’s patent
holdings have made it the sole provider of BRCA testing in the United States).
24. Complaint ¶ 31, Ass’n for Molecular Pathology v. U.S. Patent & Trademark
Office, 702 F. Supp. 2d 181, 94 U.S.P.Q.2d (BNA) 1683 (S.D.N.Y. 2010) (No. 09 Civ.
4515), 2009 WL 1343027 at *14 [hereinafter AMP Complaint]. The challenged
patents include U.S. Patent No. 5,747,282 (filed June 7, 1995), U.S. Patent No.
5,837,492 (filed Apr. 29, 1996), U.S. Patent No. 5,693,473 (filed June 7, 1995), U.S.
Patent No. 5,709,999 (filed June 7, 1995), U.S. Patent No. 5,710,001 (filed June 7,
1995), U.S. Patent No. 5,753,441 (filed Jan. 5, 1996), and U.S. Patent No. 6,033,857
(filed Mar. 20, 1998). Id. ¶ 32(a)–(d).
25. The composition claims are directed toward isolated DNA sequences having
identity to both the sequence as it exists in the human body as well as to cDNA
sequences. See Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office
(Myriad), 653 F.3d 1329, 1349–50, 99 U.S.P.Q.2d (BNA) 1398, 1414 (Fed. Cir. 2011)
(including cDNA molecules in holding that isolated DNA molecules are patentable);
see also supra text accompanying note 17 (describing the difference between native
DNA and cDNA). Collectively, the patents also claim methods of analyzing or
comparing a patient’s BRCA1/2 sequence with normal or mutated sequences and a
method claim directed to a method of screening potential cancer therapeutics.
Myriad, 653 F.3d at 1334, 99 U.S.P.Q.2d (BNA) at 1402.
26. U.S. Patent No. 5,747,282 col.153 ll.57–58 (filed June 7, 1995).
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result in an increased risk of the development of breast and ovarian
27
cancer. By securing its intellectual property through these patents,
Myriad has established itself as the sole provider of commercial
genetic testing related to breast and ovarian cancer linked to the
28
BRCA1/2 genes.
On May 12, 2009, the Association for Molecular Pathology (AMP)
and nineteen other plaintiffs, including healthcare associations,
individual doctors, researchers, and patients, filed a lawsuit against
the PTO, Myriad, and ten other individual defendants in their
capacity as Directors of the University of Utah Research Foundation
29
challenging the validity of Myriad’s gene patents. AMP alleged that
the patent claims were invalid under 35 U.S.C. § 101 because “human
genes are products of nature,” and, as such, they do not constitute
30
patentable subject matter.
On March 29, 2010, the Southern District of New York granted the
plaintiffs’ motion for summary judgment, holding the patents related
31
to BRCA1/2 invalid. The court asserted that, “DNA represents the
physical embodiment of biological information, distinct in its
32
essential characteristics from any other chemical found in nature.”
By conveying information defining the construction of the human
33
body, DNA serves as a “physical embodiment of laws of nature.”
Therefore, the court concluded that the isolated DNA molecules
containing sequences found in nature were unpatentable subject
34
matter under 35 U.S.C. § 101. Myriad filed a Notice of Appeal to
27. Myriad, 653 F.3d at 1338–39, 99 U.S.P.Q.2d (BNA) at 1405.
28. AMP Complaint, supra note 24, ¶ 48. Though Myriad regularly enforces its
patents against entities providing commercial diagnostic testing, it does not enforce
its patents against research activities of academic institutions. See, e.g., Ass’n for
Molecular Pathology v. U.S. Patent & Trademark Office, 669 F. Supp. 2d 365, 379
(S.D.N.Y. 2009) (referencing a letter to a National Cancer Institute investigator
assuring her that Myriad would not interfere with her research activities despite the
fact that it had attempted to block the commercial use of BRCA1/2 by other labs),
aff’d in part, rev’d in part, 653 F.3d 1329, 99 U.S.P.Q.2d 1398 (Fed. Cir. 2011).
29. AMP Complaint, supra note 24, ¶¶ 27–29, 32.
30. Id. ¶ 102. The plaintiffs also alleged invalidity under the United States
Constitution, specifically under Article 1, Section 8, clause 8, the First Amendment,
and the Fourteenth Amendment. Id. ¶¶ 102–03. The district court ultimately
dismissed these claims under the doctrine of constitutional avoidance. Ass’n for
Molecular Pathology v. U.S. Patent & Trademark Office, 702 F. Supp. 2d 181, 238, 94
U.S.P.Q.2d (BNA) 1683, 1726 (S.D.N.Y. 2010), aff’d in part, rev’d in part, 653 F.3d
1329, 99 U.S.P.Q.2d 1398 (Fed. Cir. 2011).
31. Ass’n for Molecular Pathology, 702 F. Supp. 2d at 232, 238, 94 U.S.P.Q.2d (BNA)
at 1722, 1726.
32. Id. at 185, 94 U.S.P.Q.2d (BNA) at 1686.
33. Id. at 228, 94 U.S.P.Q.2d (BNA) at 1719.
34. Id. at 232, 94 U.S.P.Q.2d (BNA) at 1722. The courts have excluded from
patentable subject matter laws of nature, physical phenomena, and abstract ideas. See
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35

the Federal Circuit on June 16, 2010, which heard oral arguments
36
on April 4, 2011.
II. ANALYSIS
A. Section 101 Analyses Should Focus on Differences from Naturally
Occurring Compositions Rather Than Similarities
35 U.S.C. § 101 states that “[w]hoever invents or discovers any new
and useful . . . composition of matter . . . may obtain a patent
37
therefor.” This section has been broadly construed, including as
statutory subject matter “anything under the sun that is made by
38
man.” In the same breath, the Supreme Court has recognized three
judicially-created exceptions to patentability: laws of nature, physical
39
phenomena, and abstract ideas.
As previous cases illustrate, not all inventions derived from nature
supra note 8 and accompanying text. Here, the court reasoned that the “essential
characteristic” of DNA is its underlying nucleotide sequence. Ass’n for Molecular
Pathology, 702 F. Supp. 2d at 231–32, 94 U.S.P.Q.2d (BNA) at 1721. Because the
claimed invention does not differ from native DNA with regard to the underlying
sequence, the court held that the claimed DNA was not patentable subject matter, as
it was essentially an embodiment of a law of nature. Id. at 232, 94 U.S.P.Q.2d (BNA)
at 1722. The court further concluded that the claimed comparisons of DNA involved
in the diagnostic methods were simply abstract mental processes, also rendering
them unpatentable under 35 U.S.C. § 101. Id. at 232–37, 94 U.S.P.Q.2d (BNA) at
1722–25.
35. Myriad Defendants’ Notice of Appeal, Ass’n for Molecular Pathology, 702 F.
Supp. 2d 181, 94 U.S.P.Q.2d 1683 (No. 09 Civ. 4515).
36. Oral Argument, Ass’n for Molecular Pathology v. U.S. Patent & Trademark
Office (Myriad), 653 F.3d 1329, 99 U.S.P.Q.2d (BNA) 1398 (Fed. Cir. 2011) (No.
2010-1406), available at http://www.cafc.uscourts.gov/oral-argument-recordings/
2010-1406/all (click “2010-1406.mp3” link); see Ryan B. Chirnomas, AMP v.
U.S.P.T.O.: Oral Argument at the Federal Circuit, PATENT LAW PRACTICE CTR. (Apr. 5,
2011,
12:21
PM),
http://patentlawcenter.pli.edu/2011/04/05/ampvuspto/
(summarizing oral arguments in the Myriad case).
37. 35 U.S.C. § 101 (2006) (codification of the amended Patent Act of 1952).
38. Diamond v. Chakrabarty, 447 U.S. 303, 309, 206 U.S.P.Q. (BNA) 193, 197
(1980) (quoting S. REP. NO. 82-1979, at 5 (1952); H.R. REP. NO. 82-1923, at 6 (1952))
(internal quotation marks omitted); see also Bilski v. Kappos, 130 S. Ct. 3218, 3225, 95
U.S.P.Q.2d (BNA) 1001, 1005 (2010) (noting that the Supreme Court construed §
101 broadly because “Congress plainly contemplated that the patent laws would be
given wide scope” (quoting Chakrabarty, 447 U.S. at 308, 206 U.S.P.Q. (BNA) at 197)
(internal quotation marks omitted)).
39. See Chakrabarty, 447 U.S. at 309, 206 U.S.P.Q. (BNA) at 197 (citing Parker v.
Flook, 437 U.S. 584, 198 U.S.P.Q. (BNA) 193, 195 (1978) (rejecting a patent for a
mathematical formula); Gottschalk v. Benson, 409 U.S. 63, 67, 175 U.S.P.Q. (BNA)
673, 675 (1972) (rejecting a patent for a mathematical formula); Funk Bros. Seed
Co. v. Kalo Inoculant Co., 333 U.S. 127, 130, 76 U.S.P.Q. (BNA) 280, 281 (1948)
(“For patents cannot issue for the discovery of the phenomena of nature.”); O’Reilly
v. Morse, 56 U.S. (15 How.) 62, 112–21 (1854) (rejecting a claim to all use of
electromagnetism as a motive power); Le Roy v. Tatham, 55 U.S. (14 How.) 156, 175
(1853) (proposing that “a principle is not patentable”)).
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40

are necessarily excluded from patentability. Therefore, the Federal
Circuit looked to the Supreme Court’s decisions in Funk Bros. Seed Co.
41
42
v. Kalo Inoculant Co. and Diamond v. Chakrabarty to frame its
43
decision that isolated DNA molecules are patentable subject matter.
In Funk Bros., the patent-in-suit claimed a mixture of several nitrogenfixing bacteria strains that did not mutually inhibit one another,
making the mixture capable of inoculating a broader range of
44
leguminous plants than single-species cultures. The Court held that
the mixture was not patentable because no individual species within
the mixture acquired a novel use or underwent an enlargement of
45
utility.
In Chakrabarty, the Court determined that a bacterium
genetically engineered to include four naturally occurring DNA
46
plasmids was patentable subject matter. It reasoned that the claim
was not for a natural phenomenon, but for a composition of matter
“having a distinctive name, character [and] use” resulting from
47
human ingenuity. Distinguishing Funk Bros., the Chakrabarty Court
40. See, e.g., Chakrabarty, 447 U.S. at 305, 310, 206 U.S.P.Q. (BNA) at 195, 197
(validating a patent for a genetically engineered microorganism); In re Kubin, 561
F.3d 1351, 1352, 90 U.S.P.Q.2d (BNA) 1417, 1418 (Fed. Cir. 2009) (invalidating
isolated DNA molecules encoding Natural Killer Cell Activation Inducing Ligand
only for obviousness and lack of a written description); Amgen, Inc. v. Chugai
Pharm. Co., 927 F.2d 1200, 1204, 1219, 18 U.S.P.Q.2d (BNA) 1016, 1019, 1031 (Fed.
Cir. 1991) (validating and enforcing a claim of isolated DNA molecules encoding
human erythropoietin); Merck & Co. v. Olin Mathieson Chem. Corp., 253 F.2d 156,
157, 164, 116 U.S.P.Q. (BNA) 484, 485, 490 (4th Cir. 1958) (validating a patent on a
form of vitamin B12); Kuehmsted v. Farbenfabriken of Elberfeld Co., 179 F. 701, 705
(7th Cir. 1910) (enforcing a patent claiming aspirin); Union Carbide Co. v. Am.
Carbide Co., 181 F. 104, 105, 110 (2d Cir. 1910) (enforcing a patent for a form of
crystalline calcium carbide); Parke-Davis & Co. v. H. K. Mulford Co., 189 F. 95, 97,
103 (C.C.S.D.N.Y. 1911) (enforcing a patent claiming extracted adrenalin), aff’d in
part, rev’d in part, 196 F. 496 (2d Cir. 1912); In re Bergstrom, 427 F.2d 1394, 1400,
166 U.S.P.Q. (BNA) 256, 261 (C.C.P.A. 1970) (validating a patent for two types of
purified prostaglandins); In re Williams, 171 F.2d 319, 319–20, 80 U.S.P.Q. (BNA)
150, 150–52 (C.C.P.A. 1948) (upholding a claim of a laevo rotary form of a lactone
compound).
41. 333 U.S. 127, 76 U.S.P.Q. (BNA) 280 (1948).
42. 447 U.S. 303, 206 U.S.P.Q. (BNA) 193 (1980).
43. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office (Myriad),
653 F.3d 1329, 1350, 99 U.S.P.Q.2d (BNA) 1398, 1414 (Fed. Cir. 2011).
44. Funk Bros., 333 U.S. at 129–30, 76 U.S.P.Q. (BNA) at 281.
45. Id. at 131, 76 U.S.P.Q. (BNA) at 281–82. Though invalidated by the district
court for obviousness, a § 103 determination, the Court cast its decision in terms of §
101, stating that the bacteria’s non-inhibition qualities were the work of nature, “like
the heat of the sun, electricity, or the qualities of metals.” Id. at 130, 76 U.S.P.Q.
(BNA) at 281.
46. Chakrabarty, 447 U.S. at 305 n.1, 310, 206 U.S.P.Q. (BNA) at 195 n.1, 197.
47. Id. at 309–10, 206 U.S.P.Q. (BNA) at 197 (quoting Hartranft v. Wiegmann,
121 U.S. 609, 615 (1887)) (internal quotation marks omitted); see also S. REP. NO. 71315, at 6 (1930) (distinguishing a plant discovery resulting from cultivation from the
mining of a natural mineral); H.R. REP. NO. 71-1129, at 7 (1930) (same).
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noted that, due to Chakrabarty’s efforts, the bacterium acquired
characteristics markedly different from any bacterium found in
48
nature.
Thus, Supreme Court jurisprudence directs that § 101 analyses
turn on a change in a claimed composition’s identity compared with
49
what exists in nature. Rather than examining whether isolated DNA
molecules are markedly different from native DNA molecules,
however, the Southern District of New York focused on the similarity
between the information content of isolated and native DNA
50
molecules’ nucleotide sequences.
By focusing on DNA’s genetic
function of transmitting information, the district court characterized
DNA as an unpatentable law of nature, effectively creating a
categorical rule excluding all isolated gene sequences from patent
51
eligibility.
The district court’s failure to take into account
differences in chemical structure between the molecules constituted
52
an erroneous comparative analysis.
Because isolated DNA
molecules have markedly different chemical structures compared to
native DNA molecules, the Federal Circuit rejected the district court’s
“unwarranted” categorical exclusion of isolated DNA molecules from
53
patentability.
The Federal Circuit’s majority opinion further emphasized that
patentability depends on the distinctive chemical and structural
nature of isolated DNA molecules rather than their physiological use
48. Chakrabarty, 447 U.S. at 310, 206 U.S.P.Q. (BNA) at 197.
49. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office (Myriad),
653 F.3d 1329, 1351, 99 U.S.P.Q.2d (BNA) 1398, 1415 (Fed. Cir. 2011).
50. Id. at 1353, 99 U.S.P.Q.2d (BNA) at 1416. DNA sequences per se are not
patentable subject matter. See Amgen, Inc. v. Chugai Pharm. Co., No. 87-2617-Y,
1989 WL 169006, at *32, 13 U.S.P.Q.2d (BNA) 1737, 1759 (D. Mass. Dec. 11, 1989)
(stating that a sequence would be a nonpatentable natural phenomenon), aff’d in
part, vacated in part, 927 F.2d 1200, 1219, 18 U.S.P.Q.2d (BNA) 1016, 1031 (Fed. Cir.
1991).
51. Myriad, 653 F.3d at 1353, 99 U.S.P.Q.2d (BNA) at 1416. In recent years, the
Supreme Court has tended to disparage the creation of categorical rules in patent
jurisprudence. See Bilski v. Kappos, 130 S. Ct. 3218, 3227, 95 U.S.P.Q.2d (BNA) 1001,
1007 (2010) (rejecting exclusive application of the machine-or-transformation test
for § 101 determinations, which would categorically exclude business methods from
patent eligibility); KSR Int’l Co. v. Teleflex, Inc., 550 U.S. 398, 419, 82 U.S.P.Q.2d
(BNA) 1385, 1396 (2007) (same regarding use of the teaching, suggestion, or
motivation test for § 103 determinations); Chakrabarty, 447 U.S. at 314–17, 206
U.S.P.Q. (BNA) at 199–200 (rejecting a categorical rule excluding living organisms
from patent eligibility, and instead promoting legislative and executive limitations in
this field); see also Diamond v. Diehr, 450 U.S. 175, 182, 209 U.S.P.Q. (BNA) 1, 6
(1981) (cautioning courts to avoid reading into the patent laws limitations and
conditions not expressed by the legislature).
52. Myriad, 653 F.3d at 1353, 1355, 99 U.S.P.Q.2d (BNA) at 1416, 1418.
53. Id. at 1353, 99 U.S.P.Q.2d (BNA) at 1417.
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54

or benefit. Accordingly, the court observed that patent disclosures
are better described by the chemical structure of genes, even though
biologists’ primary consideration may be the function of DNA
55
molecules.
Though such assertions may appear to preclude a
utilitarian analysis, precedent requires consideration of whether the
intervention of man imparts a new utility that renders the
56
composition markedly different from nature. In fact, differences in
utility may provide guidance as to whether the chemical structure of
57
an isolated composition differs from its structure in nature.
B. Differences Between the Chemical Structures of Isolated and Native DNA
Molecules Render Isolated DNA Molecules Patentable
As the Federal Circuit concluded, Myriad’s claimed isolated DNA
molecules indisputably exist in a chemical form distinctive from
58
native DNA molecules. In their native forms, genes exist as discrete
59
lengths embedded within a contiguous DNA molecule.
Forty-six
such contiguous DNA molecules, in combination with several
structural proteins, are packaged into larger complexes called
60
chromosomes.
Isolated DNA molecules, on the other hand, are
freestanding portions of a native DNA molecule, chemically cleaved
from the chromosomal structure, representing a fraction of the DNA

54. Id., 99 U.S.P.Q.2d (BNA) at 1416.
55. See id. at 1353–54, 99 U.S.P.Q.2d (BNA) at 1416–17 (noting that the utility of
chemical substances, and therefore isolated DNA sequences, may be relevant to
obviousness and patentable subject matter determinations).
56. See id. at 1364–65, 99 U.S.P.Q.2d (BNA) at 1425 (Moore, J., concurring in
part) (concluding that not only the different chemical structure but also the
different and beneficial utility resulting from that chemical structure makes isolated
DNA molecules patentable).
57. See, e.g., Merck & Co. v. Olin Mathieson Chem. Corp., 253 F.2d 156, 164, 116
U.S.P.Q. (BNA) 484, 490 (4th Cir. 1958) (upholding patentability of a fermentationproduced vitamin B12 compound having higher activity levels than vitamin B12
produced in the liver because the development resulted in increased therapeutic and
commercial worth); Union Carbide Co. v. Am. Carbide Co., 181 F. 104, 107 (2d Cir.
1910) (holding crystalline product patentable where physical properties were better
suited for commercial use in gas generators than those of the natural amorphous
product); Kuehmsted v. Farbenfabriken of Elberfeld Co., 179 F. 701, 705 (7th Cir.
1910) (upholding a patent for a form of aspirin purified by a process resulting in an
increased therapeutic effect compared to aspirin purified by previous methods);
Parke-Davis & Co. v. H. K. Mulford Co., 189 F. 95, 103 (C.C.S.D.N.Y. 1911) (holding
adrenaline patentable because purification from the adrenal gland transformed it
into a new substance commercially and therapeutically), aff’d in part, rev’d in part, 196
F. 496 (2d Cir. 1912).
58. Myriad, 653 F.3d at 1353, 99 U.S.P.Q.2d (BNA) at 1417.
59. Id., U.S.P.Q.2d (BNA) at 1416; LODISH ET AL., supra note 13, at 4, 8.
60. Myriad, 653 F.3d at 1352, 99 U.S.P.Q.2d (BNA) at 1415; LODISH ET AL., supra
note 13, at 8.
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61

molecule as found in nature. For example, BRCA1, despite residing
on a chromosome containing approximately eighty million
62
nucleotides, comprises only about eighty thousand nucleotides.
Such isolation requires chemical modification through severing of
the covalent bonds in the backbone of the larger contiguous DNA
molecule, and structural modification by disassociating the DNA
63
molecule from chromosomal structural proteins. Thus, the human
intervention required to isolate a specific DNA molecule imparts a
chemical identity on such isolated DNA molecules distinct from
64
native DNA molecules.
Accordingly, the BRCA1/2 molecules
claimed by Myriad are not the same as BRCA1/2 molecules as they
65
exist in the body.
In addition, the markedly different chemical structure of isolated
DNA compared to that of native DNA is critically important to the
66
isolated DNA molecule’s utility. Isolation allows scientists to focus
on the sequence of interest by removing potentially confounding
67
sequences naturally present in the larger chromosomal DNA.
Isolation also renders DNA molecules useful as physical probes and
68
primers to identify genetic mutations. Native DNA molecules simply
61. Myriad, 653 F.3d at 1352, 99 U.S.P.Q.2d (BNA) at 1415.
62. Id., 99 U.S.P.Q.2d (BNA) at 1415 (further explaining that BRCA1 cDNA, with
the exclusion of introns, consists of approximately 5500 nucleotides). Some of
Myriad’s claims cover isolated DNAs having as few as fifteen nucleotides of a BRCA
sequence. U.S. Patent No. 5,747,282 col.153, ll.66–67, col.154, ll.56–57 (filed June 7,
1995) (claims five and six).
63. Myriad, 653 F.3d at 1352, 99 U.S.P.Q.2d (BNA) at 1415. A covalent bond
defines the boundary between one molecule and another, in this case separating one
chemical species from another. Id. at 1353, 99 U.S.P.Q.2d (BNA) at 1416. Such
disassociation can be likened to the purification of prostaglandins in In re Bergstrom.
427 F.2d 1394, 1401 & n.10, 166 U.S.P.Q. (BNA) 256, 261–62 & n.10 (C.C.P.A. 1970)
(noting that purified prostaglandins were not naturally occurring because they were
not found in nature in their pure form, separate from all heterogeneous or
extraneous matter).
64. Myriad, 653 F.3d at 1353, 99 U.S.P.Q.2d (BNA) at 1416. Isolation of a DNA
molecule changes its size, inter alia, thereby altering its chemical identity. Similarly,
in Diamond v. Chakrabarty, the addition of DNA to a microorganism resulted in a
change in the microorganism’s chemical identity. 447 U.S. 303, 309–10, 206
U.S.P.Q. (BNA) 193, 197 (1980).
65. Myriad, 653 F.3d at 1352, 99 U.S.P.Q.2d (BNA) at 1415.
66. Myriad’s Memo, supra note 5, at 31.
67. See Myriad, 653 F.3d at 1365, 99 U.S.P.Q.2d (BNA) at 1424 (Moore, J.,
concurring in part) (describing isolated DNA molecules as truncations); see also
Kuehmsted v. Farbenfabriken of Elberfeld Co., 179 F. 701, 704–05 (7th Cir. 1910)
(emphasizing the claimed aspirin’s increased therapeutic effect compared to aspirins
purified by previous methods); Parke-Davis & Co. v. H. K. Mulford Co., 189 F. 95, 103
(C.C.S.D.N.Y. 1911) (highlighting the therapeutic utility gained by purifying insulin
from surrounding glandular tissue), aff’d in part, rev’d in part, 196 F. 496 (2d Cir.
1912).
68. Myriad, 653 F.3d at 1365, 99 U.S.P.Q.2d (BNA) at 1425 (Moore, J.,
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do not have the chemical and structural properties needed to
69
Therefore, isolated DNA molecules’
perform such functions.
usefulness in diagnostic genetic testing constitutes an expansion of
70
their range of utility as compared to native DNA molecules.
C. Maintaining Patent Eligibility of Isolated DNA Sequences Comports With
Longstanding PTO Practice
Since 2001, PTO policy has explicitly allowed patenting of isolated
DNA molecules with the same sequence as naturally occurring genes,
reasoning that DNA molecules do not exist in isolated form in
71
Prior to promulgating the current guidelines, the PTO
nature.
began granting patents for human genes in the 1980s, issuing at least
72
2600 patents claiming isolated DNA over the past twenty-nine years.
In the three decades that patents have been issued for isolated DNA
molecules, Congress has refrained from intervening to exclude those
73
inventions from the broad scope of § 101.
The biotechnology
concurring in part); Myriad’s Memo, supra note 5, at 32; see, e.g., U.S. Patent No.
5,693,473 (filed June 7, 1995) (disclosing the use of isolated DNA molecules
encoding BRCA1 as probes for screening patients to determine if they carry specific
BRCA1 mutations resulting in a predisposition for developing cancer); see also
USPTO Utility Examination Guidelines, 66 Fed. Reg. 1092, 1094 (Jan. 5, 2001)
(asserting that an isolated DNA molecule meets the statutory utility requirement if it
hybridizes near and serves as a marker for a disease gene).
69. Myriad, 653 F.3d at 1365, 99 U.S.P.Q.2d (BNA) at 1425 (Moore, J.,
concurring in part); Myriad’s Memo, supra note 5, at 9; see also Ass’n for Molecular
Pathology v. U.S. Patent & Trademark Office, 702 F. Supp. 2d 181, 196, 94
U.S.P.Q.2d (BNA) 1683, 1694–95 (S.D.N.Y. 2010) (acknowledging that isolated DNA
can be used as a tool for biotechnological applications for which native DNA cannot
be used), aff’d in part, rev’d in part, 653 F.3d 1329, 99 U.S.P.Q.2d 1398 (Fed. Cir.
2011).
70. Myriad, 653 F.3d at 1365, 99 U.S.P.Q.2d (BNA) at 1425 (Moore, J.,
concurring in part) (quoting Funk Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S.
127, 131, 76 U.S.P.Q. (BNA) 280, 282 (1948)). Judge Moore continued that because
diagnostic testing “is not a natural utility,” the claimed DNA does not “serve the ends
nature originally provided.” Id. (quoting Funk Bros., 333 U.S. at 131, 76 U.S.P.Q.
(BNA) at 282) (internal quotation marks omitted). In Funk Bros., the Court, though
acknowledging the advantage in combining six non-inhibiting strains of inoculating
bacteria, emphasized that the combination “produce[d] no new bacteria, no change
in the six species of bacteria, and no enlargement of the range of their utility.” 333
U.S. at 131, 76 U.S.P.Q. (BNA) at 282. Thus, the combination, independent of any
effort of the patentee, “serve[d] the ends nature originally provided.” Id., 76
U.S.P.Q. (BNA) at 282.
71. See USPTO Utility Examination Guidelines, 66 Fed. Reg. at 1093 (stating that
an inventor’s discovery of a gene can be the basis for a patent on the isolated and
purified genetic composition as separated from other molecules with which it is
associated in nature).
72. Myriad, 653 F.3d at 1355, 99 U.S.P.Q.2d (BNA) at 1418.
73. Id., 99 U.S.P.Q.2d (BNA) at 1418; 149 CONG. REC. 18,999 (2003)
(acknowledging that many institutions have extensive patents on human genes but
declining to implement legislation affecting any of those current existing patents).
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industry’s substantial investments of time and money to secure
property rights related to DNA sequences reflect the patent system’s
74
ability to spur scientific progress. Consequently, the Supreme Court
has cautioned lower courts against adopting changes with potential to
75
disrupt the settled expectations of the inventing community.
Moreover, because the judiciary is ill-suited to determine whether
claims to isolated DNA molecules promote or inhibit “[s]cience and
76
useful [a]rts” in all but the clearest cases, any change should come
77
from Congress.
CONCLUSION
As biotechnology research intensifies, invention and discovery will
blur the line between that which is man-made and that which is
naturally occurring. Where a new and useful discovery cannot be
reproduced by nature without the aid of man, it deserves
patentability, despite any striking similarities to a product of nature.
The Myriad decision, emphasizing the historical framework to be
used in § 101 analyses, underscores the need to examine the
differences in identity between an inventive composition and a
78
product of nature. When scrutinizing composition claims, district
courts should take care to focus their § 101 analyses on differences in
chemical structure, while keeping in mind that novel utility may be
74. Myriad, 653 F.3d at 1368, 99 U.S.P.Q.2d (BNA) at 1427 (Moore, J.,
concurring in part); see David E. Adelman & Kathryn L. DeAngelis, Patent Metrics:
The Mismeasure of Innovation in the Biotech Patent Debate, 85 TEX. L. REV. 1677, 1681
(2007) (noting that empirical studies indicate that growth in the number of
biotechnology patents issued has not impaired biotech innovation).
75. See Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., 535 U.S. 722, 739,
62 U.S.P.Q.2d (BNA) 1705, 1713 (2002) (advocating following precedent upon
application of prosecution history estoppel so as to avoid destroying legitimate
expectations of inventors in their property); Warner-Jenkinson Co. v. Hilton Davis
Chem. Co., 520 U.S. 17, 32 n.6, 41 U.S.P.Q.2d (BNA) 1865, 1872 n.6 (1997)
(indicating that such changes have the potential to subvert the balances the PTO
sought to strike when issuing numerous patents that have not yet expired and would
be affected by such a decision).
76. U.S. CONST. art. I, § 8, cl. 8.
77. Myriad, 653 F.3d at 1371, 99 U.S.P.Q.2d (BNA) at 1430 (Moore, J.,
concurring in part) (suggesting that Congress’s constitutional authority and
institutional ability are needed to fully accommodate “‘the varied permutations of
competing interests that are inevitably implicated by . . . new technology’” (quoting
Sony Corp. of Am. v. Universal City Studios, Inc., 464 U.S. 417, 431, 220 U.S.P.Q.
(BNA) 665, 674 (1984))); see, e.g., Diamond v. Chakrabarty, 447 U.S. 303, 318, 206
U.S.P.Q. (BNA) 193, 201 (1980) (concluding that, until Congress takes action, the
court must take the language of § 101 as it is); Gottschalk v. Benson, 409 U.S. 63, 72–
73, 175 U.S.P.Q. (BNA) 673, 676–77 (1972) (urging that a change in § 101 requires
the broad powers of investigation that Congress progresses).
78. See supra Part II.A (emphasizing that § 101 analysis should be focused on a
claimed composition’s identity compared to what exists in nature).
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79

indicative of those differences. Accordingly, the marked differences
in chemical structure and expanded range of utility of isolated DNA
molecules when compared to native DNA molecules places them
80
squarely within § 101 patentable subject matter.
The Federal
Circuit’s approach serves to promote scientific progress by leaving
intact the settled expectations of the inventing community fostered
by the broad language of § 101, judicial precedent, and the PTO’s
81
longstanding policy and practice.

79. See id. (explaining that the Myriad majority determined that DNA chemical
structure, rather than function, be the focus of patentability).
80. See supra Part II.B (describing the use of isolated genes as probes and primers
for identification of genetic mutations as important to their utility over natural
DNA).
81. See supra Part II.C (promoting only congressional alterations to patentability
and following patentability precedent by the PTO).

